CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc., a privately-held oncology drug development company, today announced that it closed an equity financing, raising $25 million through the sale of additional shares of its Series B Convertible Preferred Stock. Xanthus’ existing investors were the sole participants in this round including, Oxford Bioscience Partners, HealthCare Ventures, GeneChem, GIMV, Hambrecht & Quist Capital Management, Still River Fund, Neomed, Kestrel Ventures, CDP Capital, CDIB BioScience Ventures, and Yasuda. This brings the total venture capital raised by the company to $88 million.
